Influence of YKL‑40 gene RNA interference on the biological behaviors of endometrial cancer HEC‑1A cells

Li,Lili; Fan,Jiangtao; Li,Dahai; Liu,Yan; Shrestha,Poonam; Zhong,Chunyan; Xia,Xiuhong; Huang,Xiaobing

doi:10.3892/ol.2018.8814

Influence of YKL‑40 gene RNA interference on the biological behaviors of endometrial cancer HEC‑1A cells

Authors:
- Lili Li
- Jiangtao Fan
- Dahai Li
- Yan Liu
- Poonam Shrestha
- Chunyan Zhong
- Xiuhong Xia
- Xiaobing Huang
View Affiliations

Affiliations: Department of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: May 25, 2018 https://doi.org/10.3892/ol.2018.8814
Pages: 1777-1784

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of chitinase‑3‑like protein 1 (YKL‑40) gene RNA interference on the biological behaviors and enhanced chemosensitivity of endometrial cancer (EC) HEC‑1A cells. YKL‑40 small interfering (si)RNA was transduced into EC HEC‑1A cells using a lentivirus. The experiment was divided into three groups: The experimental group was transfected with YKL‑40 siRNA (si‑YKL‑40); the mock‑treatment group was transfected with transfection reagent only; and the blank control group was left untreated. A reverse transcription‑quantitative polymerase chain reaction was performed to investigate the mRNA expression levels of YKL‑40. The biological behaviors, including cell proliferation, migration, invasion and apoptosis, were detected by MTT and Transwell assays, and flow cytometry (FCM) analysis, respectively. The results of the present study demonstrated that the mRNA expression levels of YKL‑40 were downregulated within HEC‑1A cells upon transfection with si‑YKL‑40 (P<0.05). The proliferative, migratory and invasive abilities of HEC‑1A cells were inhibited by si‑YKL‑40 (P<0.05). The mRNA expression levels of YKL‑40 were upregulated within HEC‑1A cells following treatment with cisplatin (P<0.05). FCM analysis revealed that the average cellular apoptosis rate increased following the inhibition of YKL‑40 gene expression via siRNA (P<0.05). Therefore, the YKL‑40 gene may be associated with the proliferative, migratory, invasive and anti‑apoptotic ability of HEC‑1A cells. YKL‑40 downregulation may enhance the sensitivity of human EC HEC‑1A cells to chemotherapy.

View Figures

View References

1	Brøchner CB, Johansen JS, Larsen LA, Bak M, Mikkelsen HB, Byskov AG, Andersen CY and Møllgård K: YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem. 60:188–204. 2012. View Article : Google Scholar : PubMed/NCBI
2	Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, Yan W, Bentley B and Shao R: Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 286:15332–15343. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, et al: Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 206:1149–1166. 2009. View Article : Google Scholar : PubMed/NCBI
4	Fan JT, Si XH, Liao Y and Shen P: The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet. 287:111–115. 2013. View Article : Google Scholar : PubMed/NCBI
5	Li LL, Fan JT, Li DH and Liu Y: Effects of a small interfering RNA targeting YKL-40 gene on the proliferation and invasion of endometrial cancer HEC-1A cells. Int J Gynecol Cancer. 26:1190–1195. 2016. View Article : Google Scholar : PubMed/NCBI
6	Chiang YC, Lin HW, Chang CF, Chang MC, Fu CF, Chen TC, Hsieh SF, Chen CA and Cheng WF: Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget. 6:39740–39755. 2015. View Article : Google Scholar : PubMed/NCBI
7	Lax SF: Pathology of endometrial carcinoma. Adv Exp Med Biol. 943:75–96. 2017. View Article : Google Scholar : PubMed/NCBI
8	Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier A, et al: Reproductive risk factors and endometrial cancer: The European prospective investigation into cancer and nutrition. Int J Cancer. 127:442–451. 2010.PubMed/NCBI
9	Zhu Y, Shen J, Gao L and Feng Y: Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway. Oncol Rep. 35:2391–2397. 2016. View Article : Google Scholar : PubMed/NCBI
10	Roslind A and Johansen JS: YKL-40: A novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol. 511:159–184. 2009. View Article : Google Scholar : PubMed/NCBI
11	Steponaitis G, Skiriutė D, Kazlauskas A, Golubickaitė I, Stakaitis R, Tamašauskas A and Vaitkienė P: High CHI3L1 expression is associated with glioma patient survival. Diagn Pathol. 11:422016. View Article : Google Scholar : PubMed/NCBI
12	Thongsom S, Chaocharoen W, Silsirivanit A, Wongkham S, Sripa B, Choe H, Suginta W and Talabnin C: YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Tumour Biol. 37:9451–9463. 2016. View Article : Google Scholar : PubMed/NCBI
13	Johansen JS, Christensen IJ, Jørgensen LN, Olsen J, Rahr HB, Nielsen KT, Laurberg S, Brünner N and Nielsen HJ: Serum YKL-40 in risk assessment for colorectal cancer: A prospective study of 4,496 subjects at risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 24:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wang XW, Cai CL, Xu JM, Jin H and Xu ZY: Increased expression of chitinase 3-like 1 is a prognosis marker for non-small cell lung cancer correlated with tumor angiogenesis. Tumour Biol. 36:901–907. 2015. View Article : Google Scholar : PubMed/NCBI
15	Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, et al: Circulating and tissue expression levels of YKL-40 in renal cell cancer. J Urol. 195:1120–1125. 2016. View Article : Google Scholar : PubMed/NCBI
16	Thorn AP, Daugaard S, Christensen LH, Christensen IJ and Petersen MM: YKL-40 protein in osteosarcoma tumor tissue. APMIS. 124:453–461. 2016. View Article : Google Scholar : PubMed/NCBI
17	Lai T, Chen M, Deng Z, L Y, Wu D, Li D and Wu B: YKL-40 is correlated with FEV1 and the asthma control test (ACT) in asthmatic patients: Influence of treatment. BMC Pulm Med. 15:12015. View Article : Google Scholar : PubMed/NCBI
18	Gudmundsdottir S, Lieder R, Sigurjonsson OE and Petersen PH: Chitosan leads to downregulation of YKL-40 and inflammasome activation in human macrophages. J Biomed Mater Res A. 103:2778–2785. 2015. View Article : Google Scholar : PubMed/NCBI
19	Zou L, He X and Zhang JW: The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz J Med Biol Res. 43:1232–1238. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fan JT, Li MJ, Shen P, Xu H, Li DH and Yan HQ: Serum and tissue level of YKL-40 in endometrial cancer. Eur J Gynaecol Oncol. 35:304–308. 2014.PubMed/NCBI
21	Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M and Saygılı U: Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol. 140:64–69. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, Nishiyama A, Fei Z, Zhang X and Tamiya T: Association between YKL-40 and adult primary astrocytoma. Cancer. 116:2688–2697. 2010.PubMed/NCBI
23	Kawada M, Seno H, Kanda K, Nakanishi Y, Akitake R, Komekado H, Kawada K, Sakai Y, Mizoguchi E and Chiba T: Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 31:3111–3123. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chen CC, Pekow J, Llado V, Kanneganti M, Lau CW, Mizoguchi A, Mino-Kenudson M, Bissonnette M and Mizoguchi E: Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia. Am J Pathol. 179:1494–1503. 2011. View Article : Google Scholar : PubMed/NCBI
25	Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, et al: YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. Oncol Rep. 32:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
26	van Linde ME, van der Mijn JC, Pham TV, Knol JC, Wedekind LE, Hovinga KE, Aliaga ES, Buter J, Jimenez CR, Reijneveld JC and Verheul HM: Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. J Neurooncol. 129:221–230. 2016. View Article : Google Scholar : PubMed/NCBI
27	Boisen MK, Madsen CV, Dehlendorff C, Jakobsen A, Johansen JS and Steffensen KD: The prognostic value of plasma YKL-40 in patients with chemotherapy-resistant ovarian cancer treated with bevacizumab. Int J Gynecol Cancer. 26:1390–1398. 2016. View Article : Google Scholar : PubMed/NCBI
28	Ku BM, Lee YK, Ryu J, Jeong JY, Choi J, Eun KM, Shin HY, Kim DG, Hwang EM, Yoo JC, et al: CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer. 128:1316–1326. 2011. View Article : Google Scholar : PubMed/NCBI
29	Jefri M, Huang YN, Huang WC, Tai CS and Chen WL: YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer. 15:5902015. View Article : Google Scholar : PubMed/NCBI
30	Mylin AK, Abildgaard N, Johansen JS, Heickendorff L, Kreiner S, Waage A, Turesson I and Gimsing P: Nordic Myeloma Study Group; Serum YKL-40: A new independent prognostic marker for skeletal complications in patients with multiple myeloma. Leuk Lymphoma. 56:2650–2659. 2015. View Article : Google Scholar : PubMed/NCBI
31	Jeet V, Tevz G, Lehman M, Hollier B and Nelson C: Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells. Endocr Relat Cancer. 21:723–737. 2014. View Article : Google Scholar : PubMed/NCBI